Publication details

Functional and structural characterisation of 5 missense mutations of the phenylalanine hydroxylase

Authors

PECIMONOVA Martina POLAK Emil CSICSAY Frantisek RÉBLOVÁ Kamila STOJILJKOVIC Maja LEVARSKI Zdenko SKULTETY Ludovit KADASI Ludevit SOLTYSOVA Andrea

Year of publication 2017
Type Article in Periodical
Magazine / Source General physiology and biophysics
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=5357&category_id=132&option=com_virtuemart&vmcchk=1&Itemid=1
Doi http://dx.doi.org/10.4149/gpb_2017003
Field Biochemistry
Keywords PAH mutations; Phenylketonuria; Specific activity; Chaperons; Functional study
Description Phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are a group of genetic disorders predominantly caused by mutations in the phenylalanine hydroxylase (PAH) gene. To date, more than 950 variants have been identified, however the pathogenic mechanism of many variants remains unknown. In this study, in silico prediction and in vitro prokaryotic and eukaryotic expression systems were used to functionally characterise five PAH missense variants (p.F233I, p.R270I, p.F331S, p.S350Y, and p.L358F) previously identified in Slovak and Czech patients. p.F233I, p.R270I, and p.S350Y were classified as deleterious mutations since they showed no specific activity in functional assay and no response to chaperone co-expression. Protein levels of these PAH variants were very low when expressed in HepG2 cells, and only p.S350Y responded to BH4 precursor overload by significant increase in PAH monomer, probably due to reduced rate of protein degradation as the result of proper protein folding. Variants p.F331S and p.L358F exerted residual enzymatic activity in vitro. While the first can be classified as probably pathogenic due to its very low protein levels in HepG2 cells, the latter is considered to be mild mutation with protein levels of approximately 17.85% compared to wt PAH. Our findings contribute to better understanding of structure and function of PAH mutated enzymes and optimal treatment of PKU patients carrying these mutations using BH4 supplementation.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info